Screening method and application of gene marker for predicting treatment response of Crohn's disease

A technology of gene marker and screening method, which is applied in the field of gene marker screening for predicting the response to anti-TNF-α inhibitor therapy in Crohn's disease, can solve the problem of large impact, poor response to anti-TNFα drugs, inaccurate prediction effect, etc. problems, to avoid ineffective drugs, good predictive value, and avoid the effects of disease delay

CN113744802AInactive Publication Date: 2021-12-03聂凯
0 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Publication Date
2021-12-03
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a screening method and application of a gene marker for predicting the treatment response of Crohn's disease. According to the technical scheme, the gene markers (TLR2, TREM1, CXCL1, FPR1 and FPR2) which can be used for predicting primary drug resistance of anti-TNF alpha drug treatment of patients with the Crohn disease are screened through the scheme of the invention, and a more powerful weapon can be provided for precise medication and clinical management of the patients with the Crohn disease and even patients with the inflammatory bowel disease.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of disease drug resistance research, and specifically relates to a screening method and application of gene markers for predicting Crohn's disease anti-TNF-α inhibitor treatment response. Background technique

[0002] Crohn's disease (Crohn's disease, CD) is a chronic non-specific intestinal inflammatory disease, which belongs to one type of inflammatory bowel disease (IBD) (the other is ulcerative colitis), with lifelong morbidity The curative effect and prognosis are poor, and it is prone to multiple complications, and the pathogenic mechanism is still unclear. With changes in lifestyle and diet, the incidence of Crohn's disease in my country has increased significantly in recent years. In Europe and North America, inflammatory bowel disease has gradually developed into a common disease. According to some regional studies, inflammatory bowel disease in my country The incidence of enteropathy is gradually i...

Examples

Embodiment 1

[0029] A screening method for predicting Crohn's disease treatment response gene markers, characterized in that it comprises the following steps:

[0030] S1: By searching the public GEO (Gene Expression Omnibus) database for gene chip data sets related to intestinal tissue and peripheral blood samples from clinical Crohn's disease patients, which contain the outcome data of these patients' treatment effects of anti-TNF-α inhibitors ;

[0031] S2: The genes of patients with different drug responses in the S1 discovery cohort were analyzed by R language tools for differential genes;

[0032] S3: Then the interaction network of differential genes is obtained through the String database, and the key genes that affect the efficacy of anti-TNFα drugs are further obtained through the Degree algorithm of Cytoscape software;

[0033] S4: Through the gene expression of patients with effective and ineffective anti-TNF-α inhibitors in other independent verification cohorts, confirm the ...

Embodiment 2

[0038] For TLR2, TREM1, CXCL1, FPR1, and FPR2 genes to predict the efficacy of anti-TNFα therapy in Crohn's patients, ELISA kits and qPCR kits can be designed to determine the efficacy of anti-TNFα therapy in Crohn's patients by determining the high and low expression of TLR2.